Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye disease

Ethyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi.

The capital will be used to advance therapeutic programs targeting the autoimmune disorders Graves' disease and thyroid eye disease, conditions that often occur together.

The company plans to move its lead candidates into clinical trials before the end of the year, aiming to address unmet needs in these patient populations.

Ethyreal's entry into the market reflects growing investor interest in autoimmune disease platforms and could broaden treatment options for affected patients.